Remdesivir treatment for patients with moderate to severe COVID-19

Creative Commons License

HASANOĞLU İ., Guner R., Celik I., KANAT F., Batirel A., TELLİ DİZMAN G., ...More

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.4, pp.880-887, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 52 Issue: 4
  • Publication Date: 2022
  • Doi Number: 10.55730/1300-0144.5387
  • Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.880-887
  • Keywords: COVID-19, remdesivir, antiviral, treatment, mortality
  • Istanbul University Affiliated: Yes

Abstract

Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment.